ArticleCureus2025
Oncological Outcomes of Immature Ovarian Teratoma: A 15-Year Report From a Cancer Center.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmature ovarian teratomas (IOTs) are a rare ovarian tumor, with recurrence rates varying widely depending on age and grade. Thus far, debate exists regarding the management of IOTs, especially of their recurrences.
objectiveTo review clinical characteristics and oncological outcomes of immature ovarian teratoma following primary and secondary surgery. METHODOLOGY: This retrospective cohort study was conducted in the department of surgical oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan, between July 2008 and June 2023 (15 years). All patients with pathological confirmation of IOTs were included in the study. Women were excluded if (1) details of baseline characteristics or primary treatment were unavailable, and (2) if there was no follow-up data. Non-probability consecutive sampling technique was used for the recruitment of patients. Patient demographics and disease characteristics were summarized using descriptive statistics. Progression-free survival time and overall survival were calculated from the time of surgery to the date of recurrence or the date of death. The Kaplan-Meier method was used for survival curves. Statistical analysis was performed using Statistical Product and Service Solutions (SPSS, version 23; IBM SPSS Statistics for Windows, Armonk, NY).
resultsOf 37 women, most of the patients belonged to an age group of 21-30 years (N-16, 43.2%). Stage 1a (N-18, 48.6%) and grade III disease (N-12, 32.4%). Laparotomy was performed in 91.9% (N-34) of the patients. The majority of the patients underwent unilateral salpingo-oophorectomy (N-27, 73%). Twenty-seven patients received adjuvant chemotherapy (73%). Relapse occurred in 31.5% (N-13) of the patients. However, the most common site of relapse was the liver (N-5, 13.5%). Secondary cytoreductive surgery was done in eight (61.5%) patients, while the rest of the cohort received adjuvant chemotherapy. Overall survival after a mean follow-up of 43 months was 81%.
conclusionIOT occurs most commonly in young women. The most common presentation is early stage but high grade, and fertility-sparing surgery has good oncological outcomes. With secondary cytoreductive surgery and platinum-based chemotherapy, it is possible to salvage most recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.